We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




PET Scanning Detects Colorectal Cancer Recurrence Earlier

By MedImaging staff writers
Posted on 29 Apr 2008
Routine monitoring with positron emission tomography (PET) scanning that detects alterations in the function of cells, achieves earlier detection of recurrences of colorectal cancer than traditional scanning, which simply visualizes the structure of body tissues, a prospective study has shown.

Colorectal cancer--cancer affecting the lower part of the digestive tract--is the second most common cause of cancer-related deaths in Western countries. More...
Most individuals newly diagnosed with the disease undergo surgery to completely remove their tumor. However, about half of people who have curative surgery go on to develop recurrent disease. The median survival after surgery is two years. Adjuvant chemotherapy--anticancer drug treatment given just after surgery--improves the prognosis, but one-third of patients having this treatment still suffer a recurrence within two years after surgery.

Surgery to remove metastases in the liver or lung in people who have a recurrence of colorectal cancer improves survival so that 35-40% are alive after five years. This means that it is very important to monitor patients with colorectal cancer regularly to identify recurrence as early as possible so that tumor tissue can be removed and their odds of survival improved. Most people have regular clinical examinations and computed tomography (CT) scans, which provide detailed images of structures inside the body, to look for signs of recurrence.

French researchers performed a study to determine if functional positron emission tomography (PET) imaging, which looks at the function of body cells by measuring their use of a radio-labeled isotope of glucose (18-fluorodeoxyglucose, 18FDG)--could detect recurrences of colorectal cancer earlier than CT imaging. They randomly allocated 130 patients who had undergone curative surgery for colorectal cancer followed by chemotherapy to regular follow-up with conventional tests or with PET scans.

All the patients had six follow-up appointments, starting from the ninth month after their initial surgery and continuing to 24 months or their death. They had a physical examination, measurement of biologic markers for cancer, an ultrasound scan every 3 months (replaced by abdominal CT scans after 9 and 15 months), and a chest X-ray every 6 months. Patients in the PET group also had 18FDG-PET scans after 9 and 15 months.

Results showed that recurrence occurred in 46 patients--25 in the FDG-PET group and 21 in the group having conventional follow-up. Use of PET scans revealed unexpected tumors in an additional three patients.

Recurrences were detected after a significantly shorter time with PET scanning (12.1 months, on average) compared with conventional follow-up (15.4 months, p = 0.01). Recurrences in the PET group were also more frequently cured by surgery, with 10 patients with recurrence being cured, compared with only 2 patients in the group not having PET scans.

Prof. Iradj Sobhani, from the Université Paris 12 and Hôpital Henri Mondor (Paris, France), and lead author of the study, commented, "We showed that FDG-PET is a valuable adjunct to conventional follow-up. Using this new follow-up strategy increased the rate of curative resection by allowing us to detect recurrences of colorectal cancer at an earlier stage. Regular FDG-PET monitoring in the follow-up of colorectal cancer patients may permit the earlier detection of recurrence. We would expect improved patient survival if such as [a] follow-up program was undertaken.”

PET scanners have now been developed that can detect even smaller tumors than the system used in the French study. The investigators noted that combined PET-CT scans appeared to provide more accurate diagnoses than using the techniques separately. They predicted that using combined PET-CT scans would make it easier to accurately determine the stage of a patient's cancer, although more research is needed to validate this.

The study was published online February 26, 2008 in the British Journal of Cancer.


Related Links:
Université Paris 12 and Hôpital Henri Mondor

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Monitor/Defibrillator
Zenix
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.